Merck, BioMed X extend collaboration in oncology, autoimmunity

By The Science Advisory Board staff writers

May 17, 2021 -- Merck has extended its collaboration with German company BioMed X and will start six additional research projects at the BioMed X Institute. The projects will build on research in oncology -- specifically looking at DNA damage response and RNA splicing -- and autoimmunity -- looking at intestinal epithelial barrier in autoimmune diseases.

The next joint crowdsourcing project will focus on immune senescence and mitochondrial dysfunction in regulatory T cells and other T-cell subsets that are shared in human autoimmunity and aging. Interested parties can submit a project proposal at before July 11.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here